{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:25:18Z","timestamp":1794327918143,"version":"4.9.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting \u22654 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician\u2019s choice (methotrexate or bexarotene) in CD30-expressing mycosis fungoides (MF) or primary cutaneous anaplastic large-cell lymphoma (C-ALCL). Cutaneous T-cell lymphomas often cause pruritus and pain; brentuximab vedotin improved skin symptom burden with no negative effects on quality of life. We report final data from ALCANZA (median follow-up, 45.9 months). Adults with previously treated CD30-expressing MF\/C-ALCL were randomly assigned to brentuximab vedotin (n = 64) or physician\u2019s choice (n = 64). Final data demonstrated improved responses per independent review facility with brentuximab vedotin vs physician\u2019s choice: ORR4; 54.7% vs 12.5% (P &amp;lt; .001); complete response, 17.2% vs 1.6% (P = .002). Median PFS with brentuximab vedotin vs physician\u2019s choice was 16.7 months vs 3.5 months (P &amp;lt; .001). Median time to the next treatment was significantly longer with brentuximab vedotin than with physician\u2019s choice (14.2 vs 5.6 months; hazard ratio, 0.27; 95% confidence interval, 0.17-0.42; P &amp;lt; .001). Of 44 patients in the brentuximab vedotin arm who experienced any-grade peripheral neuropathy, (grade 3, n = 6; grade 4, n = 0), 86% (38 of 44) had complete resolution (26 of 44) or improvement to grades 1\u00a0and 2 (12 of 44). Peripheral neuropathy was ongoing in 18 patients (all grades 1-2). These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician\u2019s choice in CD30-expressing MF or C-ALCL. This trial was registered at https:\/\/www.clinicaltrials.gov as #NCT01578499.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004710","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T17:19:53Z","timestamp":1631294393000},"page":"5098-5106","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":126,"title":["Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data"],"prefix":"10.1182","volume":"5","author":[{"given":"Steven M.","family":"Horwitz","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8011-4408","authenticated-orcid":false,"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Z\u00fcrich, Z\u00fcrich, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-5873","authenticated-orcid":false,"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Istitu di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 degli Studi, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-3284","authenticated-orcid":false,"given":"Oliver","family":"Bechter","sequence":"additional","affiliation":[{"name":"Department of General Medical Oncology, University Hospital Leuven, Katholieke Universiteit (KU) Leuven, Leuven, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Eradat","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pinter-Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5710","authenticated-orcid":false,"given":"Oleg E.","family":"Akilov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh, Pittsburgh, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Columbia University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5709-092X","authenticated-orcid":false,"given":"Jose A.","family":"Sanches","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of S\u00e3o Paulo Medical School, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-9639","authenticated-orcid":false,"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-2674","authenticated-orcid":false,"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies, Maria Sklodowska-Curie Institute Oncology Center, Warszawa, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Taylor","sequence":"additional","affiliation":[{"name":"ICON Cancer Care, South Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Dalle","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Public Hospice of Lyon, Claude Bernard Lyon 1 University, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-6028","authenticated-orcid":false,"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[{"name":"University Clinic for Dermatology, Johannes Wesling Medical Centre, Minden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lisano","sequence":"additional","affiliation":[{"name":"Seagen Inc, Bothell, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bunn","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Little","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology and Epworth Healthcare, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"2021120616262038100_B1","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol."},{"key":"2021120616262038100_B2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.critrevonc.2015.12.016","article-title":"Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: peripheral T-cell lymphomas","volume":"99","author":"Zinzani","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"issue":"1","key":"2021120616262038100_B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/cco.2018.12.03","article-title":"The spectrum of CD30+ T cell lymphoproliferative disorders in the skin","volume":"8","author":"Kartan","year":"2019","journal-title":"Chi Clin Oncol."},{"issue":"10","key":"2021120616262038100_B4","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood."},{"issue":"12","key":"2021120616262038100_B5","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol."},{"issue":"32","key":"2021120616262038100_B6","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and s\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021120616262038100_B7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/bjd.13849","article-title":"Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team","volume":"173","author":"Poligone","year":"2015","journal-title":"Br J Dermatol."},{"issue":"1","key":"2021120616262038100_B8","first-page":"190","article-title":"Health-related quality of life and economic implications of cutaneous T-cell lymphoma","volume":"182","author":"Semenov","year":"2020","journal-title":"Br J Dermatol."},{"issue":"1","key":"2021120616262038100_B9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpainsymman.2012.01.012","article-title":"Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma","volume":"45","author":"Wright","year":"2013","journal-title":"J Pain Symptom Manage."},{"key":"2021120616262038100_B10","author":"National Comprehensive Cancer Network\u00ae (NCCN)"},{"key":"2021120616262038100_B11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer."},{"key":"2021120616262038100_B12","first-page":"75","article-title":"Management of cutaneous T cell lymphoma: new and emerging targets and treatment options","volume":"4","author":"Li","year":"2012","journal-title":"Cancer Manag Res."},{"key":"2021120616262038100_B13","article-title":"Summary of product characteristics","author":"ADCETRIS\u00ae (brentuximab vedotin)","year":"2018"},{"key":"2021120616262038100_B14","article-title":"US prescribing information","author":"ADCETRIS\u00ae (brentuximab vedotin)","year":"2018"},{"issue":"10094","key":"2021120616262038100_B15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet."},{"issue":"15","key":"2021120616262038100_B16","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood."},{"issue":"18","key":"2021120616262038100_B17","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol."},{"key":"2021120616262038100_B18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer."},{"issue":"32","key":"2021120616262038100_B19","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-Cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol."},{"key":"2021120616262038100_B20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2018.07.305","article-title":"Updated combined analysis of two phase II studies of brentuximab vedotin in patients with mycosis fungoides and S\u00e9zary syndrome [abstract]","volume":"101","author":"Huen","year":"2018","journal-title":"Eur J Cancer."},{"issue":"1","key":"2021120616262038100_B21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood."},{"issue":"8","key":"2021120616262038100_B22","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"3","key":"2021120616262038100_B23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","article-title":"Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and S\u00e9zary Syndrome","volume":"132","author":"Corbin","year":"2017","journal-title":"J Neurooncol."},{"key":"2021120616262038100_B24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","article-title":"Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study","volume":"133","author":"Dummer","year":"2020","journal-title":"Eur J Cancer."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2024012976","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5098\/1849210\/advancesadv2021004710.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5098\/1849210\/advancesadv2021004710.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T11:27:03Z","timestamp":1638790023000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/23\/5098\/476861\/Randomized-phase-3-ALCANZA-study-of-brentuximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":24,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004710","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]}}}